Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $34.50 Consensus Target Price from Analysts

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) has been assigned an average rating of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $34.50.

Several research analysts have issued reports on SLN shares. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, March 2nd. HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a report on Friday, March 13th. Jefferies Financial Group upgraded shares of Silence Therapeutics to a “strong-buy” rating in a report on Wednesday, March 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Tuesday, April 21st.

Institutional Trading of Silence Therapeutics

Institutional investors have recently modified their holdings of the company. Two Sigma Investments LP boosted its holdings in shares of Silence Therapeutics by 6.6% in the 3rd quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock valued at $328,000 after buying an additional 3,935 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Silence Therapeutics in the 4th quarter valued at about $177,000. ADAR1 Capital Management LLC boosted its holdings in shares of Silence Therapeutics by 26.8% in the 4th quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock valued at $144,000 after buying an additional 5,000 shares in the last quarter. Massar Capital Management LP bought a new stake in shares of Silence Therapeutics in the 2nd quarter valued at about $115,000. Finally, Citadel Advisors LLC bought a new stake in shares of Silence Therapeutics in the 3rd quarter valued at about $112,000. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Price Performance

Shares of Silence Therapeutics stock opened at $7.29 on Tuesday. Silence Therapeutics has a 1 year low of $3.54 and a 1 year high of $8.40. The firm’s 50-day moving average is $6.28 and its two-hundred day moving average is $6.14. The stock has a market cap of $344.31 million, a price-to-earnings ratio of -3.90 and a beta of 1.52.

Silence Therapeutics (NASDAQ:SLN) last issued its earnings results on Friday, March 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.07. Silence Therapeutics had a negative net margin of 15,851.88% and a negative return on equity of 101.71%. The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $2.19 million. On average, equities analysts expect that Silence Therapeutics will post -1.04 earnings per share for the current year.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.